Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Preventing perioperative respiratory complications in children with recurrent respiratory symptoms

Elizabeth Graham Smith Hall PhD, MSc, BSc BAppSci PhD CRFS FANZSRS FThorSoc FERS Program Manager Honorary Research Associate 08 6319 1178

Developing clinical predictors of disease progression in children with neuromuscular disorders to prevent future respiratory failure

Graham Hall BAppSci PhD CRFS FANZSRS FThorSoc FERS Honorary Research Associate Honorary Research Associate Professor Graham Hall is an

Developing metabolomics profiles to differentiate between healthy, preschool wheeze and asthma

André Graham Ingrid Schultz Hall Laing MBChB, PhD, FRACP BAppSci PhD CRFS FANZSRS FThorSoc FERS BSc PhD Head, BREATH Team Honorary Research Associate

iPLAYCE Study

Hayley Christian BSc (1st Class Hons), PhD (Distinction) W.Aust. Head, Child Physical Activity, Health and Development; Ascend Senior Research Fellow

Study of an oral medication for infants hospitalized with Respiratory Syncytial Virus (RSV) infection

Christopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and

PneumoWA: A case-control study of the role of viral and bacterial pathogens in causing pneumonia among Western Australian children

Christopher Elke Jennifer Peter Tom Blyth Seppanen Kent Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD RN MBBS MRCP(UK) FRACP BMBS DTMH

Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A Phase II Randomized, Controlled, Observer-Blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine When Administered to Healthy Toddlers

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants (PNEU-PED-EU-1)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

1 278 279 280 281 282 1219